ERBB2 and breast carcinoma: The DEBBRAH trial (NCT04420598) showed trastuzumab deruxtecan’s effectiveness for brain metastases in HER2-low advanced breast cancer, with a 41.7% response rate and acceptable toxicity, requiring further research[243].